By Daniella Parra Lisata Therapeutics (Nasdaq: LSTA), said it has fully enrolled the pancreatic cancer cohort for the CENDIFOX trial. The company said it evaluates certepetide with FOLFIRINOX therapies in pancreatic, colon, and appendiceal cancers and the trial is being...

By Karen Roman Aktis Oncology said it appointed Dr. Ken Herrmann to the Board of Directors. Dr. Herrmann specializes in nuclear medicine and has over a decade of experience in clinical investigation, the company said. “Ken’s joining us on the...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) said the FDA allowed the beginning of a phase 1 for the clinical trial of NPM-119, its long-term mini-implant for type-2 diabetes treatment. Vivani is also advancing in the development of NPM-115...

By Daniella Parra Imperium Health and DecisionRx are teaming up to provide free Medication Therapy Optimization (MTO) to Medicare patients in Imperium’s Accountable Care Organizations (ACOs), the company said. This program aims to enhance patient outcomes and cut healthcare costs...

By Karen Roman The Duckhorn Portfolio, Inc. (NYSE: NAPA) reported net sales increased 1.4% year over year to reach $92.5 million in its Q3 2024 results. Adjusted EBITDA grew 5.3% to $37.7 million year over year and adjusted EBITDA margin...

By Karen Roman MOBILion Systems announced it is presenting the latest features of its mass spectrometry platform, MOBIE EyeOn 2.3, at the 72nd American Society for Mass Spectrometry (ASMS) Conference in California. The latest software introduces new capabilities and streamlines...

By Daniella Parra Sparrow Pharmaceuticals said its HSD-1 inhibitor, clofutriben (SPI-62), normalized urine free cortisol in over 60% of patients with endogenous Cushing’s syndrome without significantly lowering serum cortisol, minimizing the risk of adrenal insufficiency. Traditional EnCS treatments require careful...

New School photos courtesy of Dar Charity Foundation Furthering Nikita Mishin’s Educational Vision By Exec Edge Editorial Staff Education is one of the most powerful tools for social change and human development. But in many parts of the world, access...

By Daniella Parra Kohl’s Corp. (NYSE:KSS) said regular price sales increased 2.4% in the first quarter. Net sales decreased 5.3% year-over-year to $3,178 million in the quarter and the company had a loss of 24 cents per share against earnings...

By Karen Roman Movado Group, Inc. (NYSE: MOV) maintained guidance for fiscal 2025 with net sales between $700 million and $710 million, gross profit margin around 55% and operating income between $32 million to $35 million. Net sales decreased 5.7%...